Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

Abstract

Glucagon-like peptide-1 receptor agonists have become an important therapeutic option for patients with Type 2 diabetes because of their ability to lower blood glucose and help patients lose weight. There are currently three glucagon-like peptide-1 receptor agonists on the market. In the near future, albiglutide will undergo review by the US FDA for possible approval. Results from Phase I/II trials have demonstrated that albiglutide is a safe and efficacious medication for treating Type 2 diabetes. It lowers hemoglobin A1c and decreases bodyweight. It appears to have fewer gastrointestinal side effects than liraglutide. The once-weekly (or possibly longer duration) dosing of albiglutide may improve adherence. Several Phase III trials are expected to be completed in 2013. These trials will shed further light on the safety and efficacy of albiglutide.

Keywords::

• albiglutide
• albugon
• diabetes mellitus
• glucagon-like peptide-1
• glucagon-like peptide-1 receptor agonists
• obesity
• Type 2 diabetes

Financial & competing interests disclosure:

M Feinglos receives research support from Amylin; AstraZeneca; Bristol-Meyers Squibb; Lilly; GlaxoSmithKline; Medtronic; Merck; Novo Nordisk; Proctor & Gamble; Prodigy Diabetes Care, LLC; Sanofi-aventis; Tethys. Consulting and Advisory Panel: Lilly; Pfizer. Consulting only: GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.